![](https://library.celltelligence.com/wp-content/uploads/2021/10/Gilead_Announcement.png)
$0
Gilead’s (Kite) Tecartus Receives FDA Approval for R/R Adult ALL
On Friday, October 1, Gilead (Kite) announced (press release) that the FDA has granted approval for Tecartus (CD19 CAR-T) in r/r adult ALL. Of note, Tecartus is the first approved CAR-T in the US for the treatment of adult ALL. Below, Celltelligence provides insights on how Tecartus’s approval in adult ALL compares with Kymriah’s pediatric and young adult ALL indication.